Debate Over CRISPR IP and 'Right to Science'

- The central patent dispute is between the University of California (UC), representing Nobel laureates Jennifer Doudna and Emmanuelle Charpentier, and the Broad Institute of MIT and Harvard, representing scientist Feng Zhang. While Doudna and Charpentier's team first published on CRISPR-Cas9's potential in 2012, Zhang's group was the first to demonstrate its use in editing the genomes of eukaryotic cells, which include human and animal cells. - The "right to science" is a principle rooted in the 1948 Universal Declaration of Human Rights, which states that everyone has the right to "share in scientific advancement and its benefits." Advocates argue this right should ensure broad and equitable access to scientific knowledge and technologies like CRISPR, unhindered by restrictive patents. - A key legal turning point occurred when the U.S. Patent and Trademark Office (USPTO) ruled that the Broad Institute's patents on using CRISPR in eukaryotic cells did not interfere with the UC team's broader patent application. However, this decision has been subject to ongoing appeals, creating a complex and prolonged legal battle with hundreds of millions of dollars at stake. - The patent landscape is not limited to the U.S. The European Patent Office (EPO) has also been a venue for these disputes, and patent decisions have varied, with some rulings favoring the UC group, further complicating the global intellectual property picture. - Several biotech companies have been founded based on the intellectual property of the opposing sides. Editas Medicine licensed the Broad Institute's technology, while Intellia Therapeutics and CRISPR Therapeutics were co-founded by Doudna and Charpentier, respectively, tying their commercial success to the outcome of the legal disputes. - The high cost of CRISPR-based therapies, some with price tags in the millions of dollars per treatment, raises significant health equity concerns. This pricing structure could limit access to potentially curative treatments for many, concentrating benefits among the most advantaged populations. - To commercialize the technology, both UC and the Broad Institute have used "surrogate licensing," where they outsource the licensing of their patent portfolios to private companies. This model, while potentially maximizing profits for the universities, has been criticized for creating bottlenecks that can stifle broader research and innovation by granting exclusive licenses to a limited number of companies. - While CRISPR-Cas9 is the most well-known system, the patent battles extend to other Cas proteins and variations of the technology. This ongoing development of new gene-editing tools adds further layers of complexity to the intellectual property landscape as scientists and companies seek to patent these newer innovations.